{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:39:56Z","timestamp":1700602796865},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejca.2009.04.014","type":"journal-article","created":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T00:28:44Z","timestamp":1241742524000},"page":"2050-2060","source":"Crossref","is-referenced-by-count":13,"title":["The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats"],"prefix":"10.1016","volume":"45","author":[{"given":"T.","family":"Schneider-Merck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Borbath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Charette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"De Saeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Abarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"St\u00e4rkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.04.014_bib1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.04.014_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jhep.2006.01.008","article-title":"Molecular prognostication of liver cancer: end of the beginning","volume":"44","author":"Thorgeirsson","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.04.014_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0165-1110(88)90004-8","article-title":"The ras gene family and human carcinogenesis","volume":"195","author":"Bos","year":"1988","journal-title":"Mutat Res"},{"key":"10.1016\/j.ejca.2009.04.014_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","article-title":"Blocking oncogenic ras signaling for cancer therapy","volume":"93","author":"Adjei","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.04.014_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/bi972032d","article-title":"Dislodgment and accelerated degradation of ras","volume":"37","author":"Haklai","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejca.2009.04.014_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid","volume":"1452","author":"Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2009.04.014_bib7","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","article-title":"Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid","volume":"270","author":"Marom","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.04.014_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Supression of lung cancer tumor growth in a nude Mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"Zundelevich","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2009.04.014_bib9","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1073\/pnas.96.24.14019","article-title":"Novel Ras antagonist blocks human melanoma growth","volume":"96","author":"Jansen","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejca.2009.04.014_bib10","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","article-title":"A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice","volume":"18","author":"Weisz","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.014_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.cad.0000185184.64980.39","article-title":"Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells","volume":"17","author":"Santen","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2009.04.014_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<911::AID-IJC18>3.0.CO;2-4","article-title":"Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist","volume":"80","author":"Egozi","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2009.04.014_bib13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0168-8278(99)80318-3","article-title":"The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats","volume":"31","author":"Reif","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.04.014_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hep.1840130106","article-title":"Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma","volume":"13","author":"Ogato","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.04.014_bib15","first-page":"13","article-title":"Oncogenes in human primary hepatic cancer","volume":"4","author":"Gu","year":"1986","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejca.2009.04.014_bib16","first-page":"1521","article-title":"Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis","volume":"50","author":"Richards","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.04.014_bib17","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1209635","article-title":"Spreds, inhibitors of the Ras\/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors","volume":"25","author":"Yoshida","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.014_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","article-title":"Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC","volume":"130","author":"Calvisi","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2009.04.014_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20070152","article-title":"Inhibition of the ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats","volume":"114","author":"Da Silva Morais","year":"2008","journal-title":"Clin Sci"},{"key":"10.1016\/j.ejca.2009.04.014_bib20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jhep.2008.01.008","article-title":"Experimental models of hepatocellular carcinoma","volume":"48","author":"Newell","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2009.04.014_bib21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ng1481","article-title":"Application of comparative functional genomics to identify best-fit mouse models to study human cancer","volume":"36","author":"Lee","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2009.04.014_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.20538","article-title":"Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis","volume":"41","author":"Schiffer","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2009.04.014_bib23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jm00008a004","article-title":"Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth","volume":"38","author":"Marciano","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2009.04.014_bib24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ejca.2007.05.005","article-title":"The PPARgamma agonist pioglitazonz inhibits early neoplastic occurrence in the rat liver","volume":"43","author":"Borbath","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.04.014_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/01926230390173923","article-title":"Significance of hepatic preneoplasia in risk identification and early detection of neoplasia","volume":"31","author":"Bannasch","year":"2003","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ejca.2009.04.014_bib26","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/carcin\/15.11.2587","article-title":"Focal and non-focal hepatic expression of placental glutathione S transferase in carcinogen-treated rats","volume":"15","author":"Dragan","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2009.04.014_bib27","first-page":"159","article-title":"The sequential analysis of liver cell necrosis. Inhibition of diethylnitrosamine- and dimethylnitrosamine induced acute liver cell death by posttreatment with diethyldithiocarbamate","volume":"99","author":"Ying","year":"1980","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2009.04.014_bib28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3748\/wjg.v13.i16.2271","article-title":"Genetics of hepatocellular carcinoma","volume":"13","author":"Teufel","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2009.04.014_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","article-title":"Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice","volume":"61","author":"Haklai","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2009.04.014_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/scbi.2000.0318","article-title":"Apoptosis and the liver","volume":"10","author":"Kanzler","year":"2000","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2009.04.014_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.coph.2004.03.008","article-title":"The Fas signalling pathway and its role in the pathogenesis of cancer","volume":"4","author":"Houston","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejca.2009.04.014_bib32","first-page":"450","article-title":"Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression","volume":"62","author":"Zhang","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.04.014_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1007663729113","article-title":"Fas-mediated apoptosis is attenuated in preneoplastic GST-P-positive hepatocytes isolated from diethylnitrosamine-treated rats","volume":"15","author":"Nordstrand","year":"1999","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.ejca.2009.04.014_bib34","doi-asserted-by":"crossref","first-page":"G875","DOI":"10.1152\/ajpgi.00549.2002","article-title":"The future of GI and liver research: editorial perspectives III. JNK\/AP-1 regulation of hepatocyte death","volume":"284","author":"Czaja","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ejca.2009.04.014_bib35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/MCB.22.2.680-691.2002","article-title":"Supression of AKT signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in AKT-mediated Fas ligand regulation","volume":"22","author":"Suhara","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2009.04.014_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0163-7258(00)00096-6","article-title":"Death the Fas way: regulation and pathophysiology of CD 95 and its ligand","volume":"88","author":"Sharma","year":"2000","journal-title":"Pharmacol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909002779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909002779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T22:24:48Z","timestamp":1545258288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909002779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0959804909002779"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.04.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}